Pharmaceuticals

Biogen Idec (BIIB) and partner Elan Corporation (ELN) recently announced their intention to seek approval for updating the label of their multiple sclerosis therapy, Tysabri. Biogen and Elan have submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration...

Repros Therapeutics Inc. (NASDAQ: RPRX) is up slightly in pre-market trading, gaining 3 cents to $2.60, a gain of 1.2% after having a tremendous run on Thursday. On Thursday, shares of Repros gained 82% on the back of submitting more testosterone drug data. Repros Therapeutics focuses on the...

DURECT Corporation (Nasdaq: DRRX) today reported that King Pharmaceuticals, Inc. (NYSE: KG) and Pain Therapeutics, Inc. (Nasdaq: PTIE) have announced that King has resubmitted a New Drug Application for REMOXY to the U.S. Food and Drug Administration in response to a Complete Response Letter...

On CNBC's Fast Money, Zach Karabell said that he likes Sociedad Quimica y Minera (ADR) (NYSE: SQM), and wants to buy it on Monday. Sociedad Quimica y Minera (ADR) (SQM) gained 1.39%, and closed at $54.81. Dennis Gartman wants to go short on the Japanese yen. He explained that it is overbought. You...

Gilead Sciences Inc.(GILD) recently announced that it will terminate its phase III trial (ARTEMIS-IPF) studying Letairis (ambrisentan) for the treatment of idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. The study's Data Monitoring Committee (DMC) had conducted an interim analysis...

Gilead Sciences Inc.(GILD) recently announced that it will terminate its phase III trial (ARTEMIS-IPF) studying Letairis (ambrisentan) for the treatment of idiopathic pulmonary fibrosis (IPF) due to lack of efficacy. The study's Data Monitoring Committee (DMC) had conducted an interim analysis...

Repros Therapeutics Inc. (NASDAQ: RPRX) continues to move higher in the session, and is now up 67% on more than 4.4 million shares. It had been as high as $2.53 during the session, but has since come back down to $2.36. Repros Therapeutics focuses on the development of oral small molecule drugs for...

Shares of Teva Pharmaceuticals (NASDAQ: TEVA) are spiking intra-day after the FDA issued a complete response letter for Glatiramer Acetate, Teva's supplemental New Drug Application for a lower volume injection of glatiramer acetate. The FDA stated, "Unless you can provide a convincing argument...

Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that Chairman, President and Chief Executive Officer, Patrick G. LePore, will present an overview of the company's growth strategy and its three-year financial outlook on Wednesday, January 12, 2011 from 8:30 to 9:00am PST (11:30am to...

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has received a complete response letter from the U.S. Food and Drug Administration for its supplemental New Drug Application for a lower-volume injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate...

Repros Therapeutics Inc. (NASDAQ: RPRX) is skyrocketing, gaining 32% on the back of news that it submitted data to the FDA for supporting morning assessment of testosterone for men treated with Androxal, which is its drug. At last check, shares were up 44 cents to $1.85.

Repros Therapeutics (NASDAQ: RPRX) has spiked up over 30% on positive FDA data supporting morning assessment of testosterone for men treated with their treatment product Androxal.

Unconfirmed Rumors that Johnson & Johnson (JNJ) will buy Elan Corp. plc (ELN) at $13.00 a share.

It's 90 minutes into trading and there are a few stocks in the Dow Jones Index that are starting to shape the last trading day before Christmas. The 5 best % performers in the index are Alcoa (NYSE: AA), Merck (NYSE: MRK), Verizon (NYSE: VZ), Hewlett-Packard (NYSE: HPQ) and Chevron (NYSE: CVX). On...

Abbott Labs (ABT) and AstraZeneca (AZN) recently announced that they no longer intend to continue with the development of Certriad, a fixed-dose, single pill formulation of Abbott Lab's next-generation triglyceride lowering pill, TriLipix and AstraZeneca's powerful statin drug, Crestor. The...